Literature DB >> 16306861

Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.

Guillermo Gervasini1, Sonia Vizcaino, Carolina Gasiba, Juan Antonio Carrillo, Julio Benitez.   

Abstract

The goal of this study was to detect genotypic differences between Spaniards and other related populations regarding CYP3A4*1B, CYP3A5*3, and ABCB1 (MDR1) C3435T polymorphisms. DNA from 177 Spanish patients were analyzed for the presence of these mutations using PCR-restriction fragment length polymorphism or direct sequencing. The observed frequencies for CYP3A4*1B, CYP3A5*3, and C3435T alleles were within normal values in Caucasians (0.04, 0.91, and 0.5, respectively). However, 2.8% of the patients were homozygous for the wild-type CYP3A5*1 allele, an extremely uncommon genotype in other Caucasians. In addition, analysis of CYP3A4-3A5 haplotypes revealed the existence of 2 unusual subgroups: patients who were homozygous wild-type for both polymorphisms, and patients showing a CYP3A4*1A/*1B-CYP3A5*3/*3 genotype combination. The incidence of CYP3A5*1/*1 carriers and the occurrence of subjects combining the 2 above-mentioned unusual genotype combinations were more frequent in Spanish-Caucasians compared with American- or European-Caucasians. ABCB1 C3435T genotype frequencies were equally distributed between both single and combined CYP3A4 and 3A5 genotypes. These findings suggest that dose requirements for drugs metabolized by CYP3A and certain allele-disease association studies in white populations could show discrepancies in Spaniards.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16306861     DOI: 10.1097/01.ftd.0000186914.32038.a0

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  12 in total

1.  Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Authors:  Al-Motassem Yousef; Nailya R Bulatova; William Newman; Nancy Hakooz; Said Ismail; Hisham Qusa; Farah Zahran; Nidaa Anwar Ababneh; Farah Hasan; Imad Zaloom; Ghada Khayat; Rawan Al-Zmili; Randa Naffa; Ola Al-Diab
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

2.  A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.

Authors:  Sherwin K B Sy; Jules Heuberger; Sireen Shilbayeh; Daniela J Conrado; Hartmut Derendorf
Journal:  AAPS J       Date:  2013-08-30       Impact factor: 4.009

Review 3.  Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

Authors:  Alessio Provenzani; Andrew Santeusanio; Erin Mathis; Monica Notarbartolo; Manuela Labbozzetta; Paola Poma; Ambra Provenzani; Carlo Polidori; Giovanni Vizzini; Piera Polidori; Natale D'Alessandro
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

4.  Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function.

Authors:  Nikola Z Stefanović; Tatjana P Cvetković; Tatjana M Jevtović-Stoimenov; Aleksandra M Ignjatović; Goran J Paunović; Radmila M Veličković
Journal:  Exp Ther Med       Date:  2015-06-26       Impact factor: 2.447

5.  CYP3A genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study.

Authors:  Guillermo Gervasini; Guadalupe García-Pino; Esther Vergara; Sonia Mota-Zamorano; Montserrat García-Cerrada; Enrique Luna
Journal:  Eur J Clin Pharmacol       Date:  2017-10-18       Impact factor: 2.953

6.  CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.

Authors:  Yuqing Xiong; Zhao Yuan; Jingzhi Yang; Chunhua Xia; Xinhua Li; Shibo Huang; Hong Zhang; Mingyi Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-11-27       Impact factor: 2.441

7.  Polymorphism C3435T of the MDR1 gene in Central Americans and Spaniards.

Authors:  J Vicente; Blanca Sinues; A Fanlo; P Vasquez; J C Medina; B Martinez-Jarreta
Journal:  Mol Biol Rep       Date:  2007-06-19       Impact factor: 2.316

8.  CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study.

Authors:  Carmen San Jose; Agustin Cabanillas; Julio Benitez; Juan Antonio Carrillo; Mercedes Jimenez; Guillermo Gervasini
Journal:  BMC Cancer       Date:  2010-08-30       Impact factor: 4.430

9.  Pharmacogenetics may Influence Tacrolimus Daily Dose, but not Urinary Tubular Damage Markers in the Long-Term Period after Renal Transplantation.

Authors:  Nikola Z Stefanović; Tatjana P Cvetković; Radmila M Veličković-Radovanović; Tatjana M Jevtović-Stoimenov; Predrag M Vlahović; Ivana R Stojanović; Dušica D Pavlović
Journal:  J Med Biochem       Date:  2015-09-19       Impact factor: 3.402

10.  High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.

Authors:  María Barreda-Sánchez; Juan Buendía-Martínez; Guillermo Glover-López; Carmen Carazo-Díaz; María Juliana Ballesta-Martínez; Vanesa López-González; María José Sánchez-Soler; Lidya Rodriguez-Peña; Ana Teresa Serrano-Antón; Remedios Gil-Ferrer; Maria Del Carmen Martínez-Romero; Pablo Carbonell-Meseguer; Encarna Guillén-Navarro
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.